Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
Open Access
- 1 November 2020
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-11
Abstract
Background: A higher vitamin D intake improves the prognosis of early stage breast cancer (BC) patients. We hypothesized that vitamin D intake should refer to vitamin D receptor (VDR) expression. In order to prove this hypothesis, we first intend to evaluate the correlation between VDR expression and prognosis of BC patients using meta-analysis. Methods: Literatures from PubMed, Embase, and the Cochrane Library (last update by May 20, 2020) were retrieved to find studies assessing the prognostic role of VDR in BC. The hazard ratios (HRs) for patients’ survival were extracted for pooled analyses. Subgroup analysis, sensitivity analysis and meta-regression were performed to explore the sources of heterogeneity. Results: Seven articles containing eight studies with 2503 patients were enrolled. The results from the pooled analyses showed that the VDR expression generally had no relationship with BC patients’ overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and progression-free survival (PFS) (P > 0.05). Because only the number of studies exploring the relationship between VDR expression and OS is greater than five and there is heterogeneity, we explored the sources of heterogeneity of these studies. Subgroup analyses showed that the VDR expression in the nucleus had no relationship with OS, but high total VDR expression in the nucleus and cytoplasm was related to a better OS (pooled HR = 0.41; 95% CI = 0.18–0.95; P = 0.038). In addition, in subgroup of studies using cut-off values other than ‘immunoreactive score (IRS)>5’ and ‘IRS > 25′, high VDR expression was associated with a better OS (pooled HR = 0.47; 95% CI = 0.30–0.74; P = 0.001). Sensitivity analysis showed that the result pattern was not obviously affected by any single study. Meta-regression showed that the source of heterogeneity was not country (P = 0.657), pathological type (P = 0.614), molecular type (P = 0.423), staining location (P = 0.481), or cut-off value (P = 0.509). Conclusions: The protein expression level of VDR in entire BC cells evaluated by immunohistochemistry is related to the OS of BC patients. It is expected that a more individualized vitamin D intake and a more accurate prognosis assessment can be recommended for BC patients based on the VDR expression. Of course, more preclinical and clinical studies are needed.Keywords
This publication has 39 references indexed in Scilit:
- Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2013
- Vitamin D metabolism in mammary gland and breast cancerMolecular and Cellular Endocrinology, 2011
- The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast CancerJournal of Histochemistry & Cytochemistry, 2011
- A Novel Gemini Vitamin D Analog Represses the Expression of a Stem Cell Marker CD44 in Breast CancerMolecular Pharmacology, 2011
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009
- Association between Plasma 25-Hydroxyvitamin D and Breast Cancer RiskCancer Prevention Research, 2009
- Review and meta-analysis on vitamin D receptor polymorphisms and cancer riskCarcinogenesis, 2009
- Vitamin D Intake and Breast Cancer Risk in Postmenopausal WomenArchives of internal medicine (1960), 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986